Lala M Dunbar

Summary

Country: USA

Publications

  1. pmc Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study
    Charles M Fogarty
    Spartanburg Medical Research, Spartanburg, South Carolina, USA
    BMC Infect Dis 5:43. 2005
  2. ncbi request reprint Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance
    Lala M Dunbar
    Louisiana State University Medical Center, New Orleans, Louisiana 70112, USA
    Am J Med Sci 326:360-8. 2003
  3. ncbi request reprint Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults
    Lala Mathers Dunbar
    Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 26:48-62. 2004
  4. pmc Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial
    Lala M Dunbar
    LSU Health Sciences Center, School of Medicine at New Orleans, New Orleans, Louisiana 70112, USA
    Antimicrob Agents Chemother 55:3476-84. 2011
  5. ncbi request reprint Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens
    Lala M Dunbar
    Louisiana State University Medical Center, New Orleans, LA, USA
    Curr Med Res Opin 20:555-63. 2004
  6. ncbi request reprint High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm
    Lala M Dunbar
    Louisiana State University Medical Center, New Orleans, Louisiana, USA
    Clin Infect Dis 37:752-60. 2003

Collaborators

Detail Information

Publications6

  1. pmc Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study
    Charles M Fogarty
    Spartanburg Medical Research, Spartanburg, South Carolina, USA
    BMC Infect Dis 5:43. 2005
    ..Telithromycin (a new ketolide) has shown good in vitro activity against the key causative pathogens of CAP, including S pneumoniae resistant to penicillin and/or macrolides...
  2. ncbi request reprint Current issues in the management of bacterial respiratory tract disease: the challenge of antibacterial resistance
    Lala M Dunbar
    Louisiana State University Medical Center, New Orleans, Louisiana 70112, USA
    Am J Med Sci 326:360-8. 2003
    ..These promising new drugs have shown in vitro and in vivo efficacy in the treatment of community-acquired RTIs, such as community-acquired pneumonia, acute exacerbations of chronic bronchitis, and acute bacterial maxillary sinusitis...
  3. ncbi request reprint Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults
    Lala Mathers Dunbar
    Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 26:48-62. 2004
    ..Telithromycin was derived by structural modification of the basic macrolide molecule to allow tight binding to the bacterial ribosome that enhances potency and minimizes the risk for the development of resistant strains...
  4. pmc Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial
    Lala M Dunbar
    LSU Health Sciences Center, School of Medicine at New Orleans, New Orleans, Louisiana 70112, USA
    Antimicrob Agents Chemother 55:3476-84. 2011
    ..The results of this study show that single- and infrequent-dosing schedules of oritavancin were as efficacious as daily administration and had a similar safety profile in treating cSSSI caused by Gram-positive pathogens, including MRSA...
  5. ncbi request reprint Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens
    Lala M Dunbar
    Louisiana State University Medical Center, New Orleans, LA, USA
    Curr Med Res Opin 20:555-63. 2004
    ..Current recommended durations for treatment of atypical community-acquired pneumonia (CAP) range from 10 to 21 days. However, antibiotics such as the fluoroquinolones may allow for effective, short-course regimens...
  6. ncbi request reprint High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm
    Lala M Dunbar
    Louisiana State University Medical Center, New Orleans, Louisiana, USA
    Clin Infect Dis 37:752-60. 2003
    ..2% and 92.4% in the 750-mg and 500-mg groups, respectively. These data demonstrate that 750 mg of levofloxacin per day for 5 days is at least as effective as 500 mg per day for 10 days for treatment of mild-to-severe CAP...